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Quasi-enantiomeric single-nucleoside and
quasi-racemic two-nucleoside hydrochloride
salts and ruthenium complexes of cytidine
and 2′,3′-dideoxycytidine analogs unveiling
the negligible structure-driving role of the
2′,3′-moieties†
Felipe Terra Martins,*a Rodrigo S. Corrêa,b Alzir Azevedo Batistab and Javier Ellenac
Insights into the structural basis of nucleoside molecular organization have been achieved from
crystal engineering research. Here, we have investigated the role of differences at the 3′-position of the
five-membered ring in the determination of the molecular conformation and crystal packing of quasi-
enantiomeric cytidine-based nucleosides. Firstly, a hydrochloride salt of zalcitabine (2′,3′-dideoxycytidine)
isostructural to lamivudine (2′,3′-dideoxy-3′-thiacytidine) hydrochloride was prepared. The R12(6) motif
responsible for pairing between nucleosides and counterions as well as the assembly of chains and
sheets with 21-screw axis symmetry-related ionic pairs were observed in both salts, even with lamivudine
differing from zalcitabine in the opposite chirality of their C1′ and C4′ carbons and for a sulfur atom
at the 3′-position rather than a methylene group. Based on the isostructurality between zalcitabine
hydrochloride and lamivudine hydrochloride, but with crystal structures which are quasi-enantiomeric,
a hydrochloride salt having both nucleosides in a single crystal form was designed in this study. The
obtained hybrid structure is a quasi-racemate in which chains assembled with R12(6)-paired lamivudine
and chloride can be related by pseudo inversion symmetry to that of zalcitabine and chloride but with an
antiparallel growth direction. In addition, the first examples of ruthenium(II) coordination complexes with
cytidine nucleosides are reported here. The trans-bis-(triphenylphosphine)(lamivudinate)(2,2′-bipyridine)
ruthenium(II) perchlorate and trans-bis-(triphenylphosphine)(cytidinate)(2,2′-bipyridine)ruthenium(II) perchlorate
complexes have the same coordination geometry and similar chains made up of complex units intercalated
by water despite major molecular difference given by 2′-CH2 and 3′-S moieties in lamivudinate rather than
CH2OH ones in both positions of cytidinate.
1. Introduction
The comprehension of the structural phenomenon driving
molecular assembly in crystals has been extensively investi-
gated nowadays.1 Supramolecular functionality and synthon
concepts have provided an advance in understanding on why
certain packing frameworks are frequently found in crystals
while others are not.2 Besides simplifying the interpretation
of complex crystal architectures by means of recognition of
the most frequent intermolecular interaction patterns, these
concepts allow one to predict how molecules will be assem-
bled into supramolecular motifs.3 Sometimes, even crystal
systems and space groups can be successfully predicted on
the basis of the recognition of robust synthons and the per-
sistence of supramolecular motifs.4 Once the role of synthons
and crystal packing entities in the structural assembly can be
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understood in practice, crystal engineers can explore them to
design new polymorphs and multicomponent molecular crys-
tals with desired solid state properties. In fact, a crystal engi-
neering strategy based on such knowledge is one of the most
important routes to modulate and fine tune the macroscopic
features of a functional material in the solid state.5 Concerning
pharmaceuticals, several performance improvements, such as
increasing in solubility, dissolution rate, stability and flow
property among others, have been achieved with crystal forms
rationally conceived by invoking synthons and intermolecular
isostructurality.6 In this sense, multicomponent molecular
crystals of active pharmaceutical ingredients (APIs) are widely
investigated due to the welcome possibility of manipulating a
functional and/or technical feature in association with practical
preparation procedures chemically designed without serendip-
ity, higher yield, reproducibility, and purity.7
Lamivudine (β-L-2′,3′-dideoxy-3′-thiacytidine, 3TC) is an
API of the nucleoside reverse transcriptase inhibitor (NRTI)
class used against both AIDS (HIV) and hepatitis B (HBV)
viruses. It was originally marketed by the pharmaceutical
company GlaxoSmithKline under the brand name EPIVIR®.
This drug is a remarkable example in which crystal engineer-
ing can be successfully employed to improve its solid state
properties related to pharmaceutical performance.8 Solubility
has been increased with salts thereof.8 Besides this, lamivudine
is a small molecule template which gives insight into the under-
standing of multicomponent molecular crystal formation
in NRTIs as well as in nucleic acid double-stranded helix
assembly,9 becoming an attractive API for crystal engineering
research.
For instance, synthon conservation and isostructurality
has been demonstrated to occur in lamivudine salts with
saccharin and maleic acid, even with their great molecular
differences, revealing the robustness of the R22(8)10 hydrogen-
bonded cycle responsible for the pairing between a drug
and counterions and the persistence of supramolecular
motifs as chains and sheets made up of 21-screw axis symme-
try related ionic pairs.4 On the other hand, such a synthon
was not observed in hydrogen phthalate salts anhydrate and
hemihydrate of lamivudine having a counterion with the
same synthon ability as the other two salts.5
The lamivudine molecule presents two chiral carbons,
C1′ and C4′, with S and R absolute configurations. It is
known that its anhydrous form II is isostructural to zalcitabine
(2′,3′-dideoxycytidine).11 This is also an NRTI API marketed
under the brand name HIVID® by Roche, but it is little used
for anti-HIV therapy nowadays. It differs from lamivudine in the
opposite chirality of its C1′ and C4′ carbons (R and S, respec-
tively), and by the 3′-CH2 group in the five-membered ring
instead of the 3′-sulphur in the counterpart. Both cytidine-like
nucleosides exhibit the same packing and conformation into
tetragonal unit cells containing enantiomorphic symmetry ele-
ments, namely, P43212 (lamivudine) and P41212 (zalcitabine).
Therefore, the isostructurality of lamivudine and zalcitabine
provides a clue on their ability to form quasi-enantiomeric crys-
tals even if their 3′-position moiety is not the same.
Here, we study whether the ability of lamivudine and
zalcitabine to form quasi-enantiomeric crystals could be
extended to multicomponent crystal forms containing
them. For this purpose, and based on the known synthetic
route of lamivudine hydrochloride (1),12 a hydrochloride salt
of zalcitabine was prepared. Zalcitabine hydrochloride (2) is
isostructural to 1. Based on this, we proceed to co-crystallize
both APIs. Interestingly, lamivudine zalcitabine hydrochloride
(3) crystallized as a quasi-racemate, with both APIs related by
a pseudo inversion center. These results show the meaning-
less role of differences at the 3′-position in the determination
of molecular conformation and crystal packing (see Scheme 1
for chemical structures). Furthermore, in this study we pre-
pared the first examples of ruthenium(II) complexes with
cytidine-like ligands, namely, trans-[Ru(PPh3)2(3TC)(bipy)]
ClO4 (4) and trans-[Ru(PPh3)2(CYD) (bipy)]ClO4 (5), where PPh3
means tryphenylphosphine, bipy refers to 2,2′-bipyridine, and
the ligands 3TC and CYD are lamivudinate and cytidinate,
respectively. Ruthenium complexes with nucleosides are
known only with adenosine monophosphate and guanosine,13
while cytidine and its analogs are shown only to form coordina-
tion complexes with osmium.14 Despite the differences
Scheme 1 Chemical of structures of the multicomponent crystal forms and ruthenium coordination complexes studied here.
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determined by the presence of CH2OH moieties at the 2′ and 3′
positions of cytidine rather than CH2 and S in lamivudine, both
complexes show the same coordination geometry. Moreover,
they present assemblies of supramolecular chains made
up of translation symmetry related complexes intercalated by
water units.
2. Material and methods
2.1 Preparation of 2 and 3
Anhydrate forms of lamivudine and zalcitabine were used for
the preparation of 2 and 3. Lamivudine was acquired from the
Instituto Nacional de Controle de Qualidade, FIOCRUZ
(lamivudine purity of 99.55 ± 0.07 mol% and melting tempera-
ture of 175.6 ± 0.3 °C, both determined by differential scanning
calorimetry according to the ASTM E928 standard specifica-
tion). Zalcitabine was purchased from Sigma-Aldrich® (HPLC
grade). Some crystals of both APIs were directly isolated from
their sample batch and were first analyzed by the single crystal
X-ray diffraction technique prior to using them in the prepara-
tion of 2 and 3. Indexed unit cell constants matched those
reported in the literature for their anhydrated crystal struc-
tures, which confirmed the authenticity of the samples.
The preparation of 2 follows the procedure described pre-
viously for the synthesis of 1,12 but changing the API. Zalcita-
bine (10 mg, 0.04 mmol) was dissolved in isopropyl alcohol
(5 ml, 66 mmol) in a water bath (308 K) with stirring (5 min).
Next, a 0.28 mol L−1 solution of hydrochloric acid in water
(0.25 ml, 0.07 mmol) was added with stirring (5 min, 298 K)
to the room temperature cooled solution of zalcitabine in iso-
propyl alcohol. Plate-shaped crystals of 2 were grown on the
bottom of glass crystallizers after slow evaporation of the acid
solution upon standing (7 days, 298 K). The same protocol was
used for the preparation of 3, expect for the simultaneous dis-
solution of both lamivudine (5 mg, 0.022 mmol) and zalcita-
bine (5 mg, 0.023 mmol) in isopropyl alcohol (5 ml, 66 mmol),
then following the subsequent procedures described above.
2.2 Synthesis of 4 and 5
Complexes 4 and 5 were synthesized using the same procedure
and using cis-[RuCl2(PPh3)2(bipy)] as the starting complex,
which was prepared according to the literature.15 The ligand
lamivudine (0.12 mmol, 28.0 mg) or cytidine (0.12 mmol,
30.0 mg) was dissolved in 50 mL of a mixture of dichloromethane–
methanol (1 : 1 v/v) with 20 μL of triethylamine and NaClO4
(0.12 mmol; 15.0 mg). After, 100 mg (0.11 mmol) of the
cis-[RuCl2(PPh3)2(bipy)] precursor was added, each reaction
was kept under reflux and stirred for 24 h under an argon
atmosphere. The final orange solutions were concentrated to
ca. 2 mL and 10 mL of water was added in order to obtain an
orange precipitate. The solids were filtered off and washed
with warm water and diethyl ether and dried under vacuum. Single
crystals of 4 were grown by slow evaporation of an acetone–
water (9 : 1 v/v) mixture at room temperature, whereas crystals of
5 were grown by diffusing diethyl ether into a dichloromethane
solution of the complex.
(4): yield of 110 mg (85%). Anal. calc. for
RuC54H48N5O3P2S·ClO4·H2O: exp. (calc) C, 57.38 (57.52); H,
4.40 (4.47); N, 6.15 (6.21); S, 2.76 (2.84)%. Molar conductance
(μS cm−1, CH2Cl2) 28.2.
31P{1H} NMR (162 MHz, CDCl3, 298 K):
δ(ppm) 36.8 (s); 1H NMR (400 MHz, CDCl3, 298 K): δ(ppm)
10.50 (1H, C7–H of bipy) and 9.30 (1H, C16–H of bipy);
7.50–6.90 (30H aromatic hydrogen atoms of PPh3 and 6H
aromatic hydrogen atoms of bipy); 6.47 (1H, C6–H of 3TC);
6.01 (1H, C1′–H of 3TC); 5.28 (1H, C4′–H of 3TC);
4.48 (1H, C5–H of 3TC); 3.93 and 3.81 (2H, C5′–H of 3TC);
3.19 and 2.81 (2H, C2′–H of 3TC). 13C NMR (400 MHz, CDCl3,
298 K): δ(ppm) 169.6 (C4); 158–156 (C2 and 4C of bipy);
135–121 (6C of bipy, 36C of PPh3 and C6 of 3TC); 96.4 (C5);
87.9 (C1′); 83.9 (C4′); 64.6 (C5′); 35.9 (C5′). UV-Vis (CH2Cl2, 10
−5 M):
λ/nm (ε/mol−1 L cm−1) 338 (8.920 × 103), 436 (3.768 × 103).
(5): yield of 100 mg (77%). Anal. calc. for
RuC55H50N5O5P2S·ClO4·2H2O·CH3OH: exp. (calc) C, 56.62(56.45);
H, 5.03(4.91); N, 5.84(5.88)%. Molar conductance (μS cm−1,
CH2Cl2) 22.7.
31P{1H} NMR (162 MHz, CDCl3, 298 K): δ(ppm)
37.7 (s); 1H NMR (400 MHz, CDCl3, 298 K): δ(ppm) 10.46
(1H, C7–H of bipy) and 9.23 (1H, C16–H of bipy); 7.50–6.90
(30H aromatic hydrogen atoms of PPh3 and 6H aromatic hydro-
gen atoms of bipy); 6.49 (1H, C6–H of CYD); 5.78 (1H, C1′–H of
CYD); 5.33 (1H, C4′–H of CYD); 4.98 (1H, C5–H of CYD); 3.35
and 3.23 (1H, C3′–H and C2′–H of CYD); 3.90 and 2.82 (2H, C5′–H
of CYD). 13C NMR (400 MHz, CDCl3, 298 K): δ(ppm) 169.6 (C4);
158–156 (C2 and 4C of bipy); 136–121 (6C of bipy, 36C of
PPh3 and C6 of CYD); 95.4 (C5); 86.0 (C1′); 75.4 (C4′); 71.4 (C3′);
65.9 (C2′); 62.4 (C5′). UV-Vis (CH2Cl2, 10
−5 M): λ/nm (ε/mol−1 L cm−1)
340 (7.244 × 103), 440 (3.998 × 103).
2.3 Structure determination
Well-grown single crystals of 2–5 were selected after full solvent
matrix evaporation. They were mounted on a κ-goniostat and
exposed at room temperature to a graphite-monochromated
X-ray beam (Mo Kα, λ = 0.71073 Å) using an Enraf-Nonius
Kappa-CCD diffractometer equipped with a CCD camera of
95 mm. In the case of 2 and 3, low-temperature data collec-
tion was also performed using a cold N2 gas blower cryogenic
device (Oxford Cryosystem, Oxford), revealing the inexistence
of crystal-to-crystal phase transformation between the evalu-
ated temperature range based on the fact that there are no
straight differences in the unit cell constants (see Table S1,
ESI†) and the solved structures do not differ under room and
low temperature X-ray diffraction data collection.
The room temperature X-ray diffraction data of 3 had low
intensity even at medium resolution. Consequently, a dataset of
nonsatisfactory overall quality was achieved. However, fortu-
nately, this was not observed for the dataset collected at low
temperature. Refinements on the low temperature data were
stable and converged more easily, resulting in acceptable R-factors
for the crystal structure of 3. Furthermore, a positional disorder
in the whole hydroxymethylene branch of lamivudine in 3 can
be reliably modeled based on the low temperature dataset. This
disorder was refined over two occupancy sites for each atom of
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the 5′-CH2OH moiety, with constrained site occupancy (s.o.)
factors of 60% (the atom fractions labeled as C5′L, H5′xL, H5′yL,
O5′L and H5′OL) and 40% (the atom fractions labeled as
C5′L′, H5′xL′, H5′yL′, O5′L′ and H5′OL′).
The crystallographic software used is as follows: COLLECT16
(X-ray diffraction collect strategy with φ scans and ω scans and
with κ offsets, besides frame acquisition monitoring), HKL
Denzo–Scalepack17 package of softwares (indexing, integration
and scaling of raw data), SHELXS-9718 (structure solving),
SHELXL-9718 (structure refinement), MERCURY19 and ORTEP-320
(structure analysis and graphical representations). The structures
were solved using the direct methods of phase retrieval. All non-
hydrogen atoms of the asymmetric unit were promptly assigned
from the electronic density Fourier synthesis, their positional
and thermal parameters then refined by the full-matrix least
squares method based on F2. Free anisotropic and fixed isotropic
atomic displacement parameters were set for non-hydrogen and
hydrogen atoms, respectively. The isotropic thermal displace-
ment parameters of the C–H and N–H hydrogen atoms were
20% greater than the equivalent isotropic parameter of the corre-
sponding atom. For the O–H hydrogen atoms, this percentage
was set to 50%. Concerning the positions of hydrogens, C–H
bond distances were stereochemically defined according to a
riding model. Therefore, their positional parameters were
constrained in the refinements. The coordinates of the O–H,
N–H and N+–H hydrogen atoms were primarily defined as
those of the electronic density peaks located from the differ-
ence Fourier map and refined freely in 2, contrary to 3–5 in
which their coordinates were fixed following the riding model
after the residual electronic density peak corresponding to the
O–H, N–H and N+–H hydrogen atoms have been properly
identified from the difference Fourier map.
3. Results and discussion
We have previously obtained 1 from a solvent matrix made
up of a 0.28 mol L−1 solution of hydrochloric acid in water
(0.25 mL) and isopropyl alcohol (5 mL).12 Based on the
isostructurality of the anhydrous forms of lamivudine and
zalcitabine11 crystallizing in the enantiomorphic tetragonal
space groups P43212 and P41212, respectively, we were interested
in knowing whether both APIs could crystallize together in a
multicomponent salt. In fact, lamivudine and zalcitabine
are 2′,3′-dideoxycytidine analogs differing in a sulfur atom at
3′-position in the first rather than a methylene group in the last
and in the chirality of their asymmetry centers. The two chiral
carbons, C1′ and C4′, show S and R absolute configurations in
lamivudine and R and S configurations in zalcitabine, respec-
tively. Based on the fact that their anhydrate phases have
quasi-enantiomeric structures,11 one can realize that the iso-
steric replacement of methylene in zalcitabine with a sulfur
atom in lamivudine at the 3′-position does not have a
structure-driving role in their molecular conformation and
intermolecular assembly. Therefore, 2 was expected to crystal-
lize isostructurally to 1, which has been successfully realized.
Salt 2 was obtained using the same solvent matrix
employed to prepare 1. The pH value was below two for the
crystallization medium of both APIs due to the hydrochloric
acid concentration in the solvent system. Considering the
pKa values of zalcitabine (4.34)
21 and lamivudine (4.30),22
the protonated forms of both drugs were at least 200-fold
more than the neutral ones in the bulk of the acid crystalliza-
tion batches, even before beginning the solvent evaporation.
In this way, the crystallization of phases only made up of pos-
itively charged drug molecules and chloride counterions was
possible. It is important to comment that the hydrochloride
salts have been obtained as isostructural solid state phases of
opposite chirality due to the use of achiral solvents such as
water and isopropyl alcohol in both cases.
Both hydrochloride salts crystallize in the P21 space group
with one cation, (drug)+, and one chloride anion in the asym-
metric units (Fig. 1 and Table S1, ESI†). The drug conforma-
tions are almost identical in 1 and 2, with the cytosine and
oxathiolane rings adopting anti and C3′-endo puckering con-
formations, respectively (see Table S2, ESI† for torsions on
the N1–C1′ bridge and into the five-membered ring describ-
ing these conformations). The hydroxyl group conformation
is also the same in both salts, assuming an equatorial posi-
tion on the same side of the CH2 or sulfur at the 3′-position
of the five-membered ring (see Table S2, ESI† for torsions
around the 5′-CH2OH branch describing this conformation).
The dihedral angles of 2 are similar to the corresponding
Fig. 1 (a) Asymmetric unit of zalcitabine hydrochloride (2) at room
temperature. Non-hydrogen atoms are represented as 50% probability
ellipsoids, while hydrogens are shown as arbitrary radius spheres.
(b) Asymmetric units and (c) crystal structure fragments of lamivudine
hydrochloride (1)12 and 2 can be related by a pseudo mirror plane
(black line).
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ones of 1, but with opposite signals. This reflects the confor-
mational similarity between them but with opposite chirality.
The crystal packing features of 1 and 2 were also con-
served. Both structures were assembled with ionic pairs made
up of a drug cation and chloride counterion held together
through two hydrogen bonds in which the protonated cyto-
sine ring of the drugs is a donor through its imine and amine
moieties to an identical in-plane chloride anion (see Table S2,
ESI† for planarity descriptors). This gives rise to a pairing with
a bifurcated hydrogen bonding motif. The other NH2 hydrogen
that is not involved in the pairing with the chloride anion in
the bifurcated hydrogen bonds also interacts with a 21-screw
axis symmetry related chloride anion, which is out of the cyto-
sine plane. Such a hydrogen bonding pattern is responsible for
the assembly of one-dimensional chains parallel to the [010]
direction made up of alternate drug cations and chloride
Fig. 2 Supramolecular structure of zalcitabine hydrochloride. One-dimensional chain viewed along the (a) (100) and (b) (010) planes. Three cross-linked
one-dimensional chains viewed along the (c) (100) and (d) (010) planes. The black circles and box denote hydrogen bonds between the 5′-hydroxyl and
2-carbonyl moieties in panel (c). The side one-dimensional chains cross-linked to the center chain displayed in panels (a) and (b) were colored blue and
red in both panels (c) and (d). (e) Completing the 3D structure by stacking cytosine rings parallel to the [100] direction. (f) Chloride channels formed paral-
lel to the [100] direction with the cytosine stacking distance depicted. Equivalent positions: i = −1 − x; 0.5 + y; 1 − z; ii = −x; 0.5 + y; −z.
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anions. Along this direction, API units related by 21-screw axis
symmetry are connected through a O–H⋯O hydrogen bond
between the 5′-hydroxyl and 2-carbonyl groups. This contact
acts as a cross-linker between the [010]-packed chains along
the [10−1] direction, giving rise to 2D sheets (Fig. 2). The 3D
crystal packing of both hydrochloride salts is completed by
face-to-tail π–π base-stacking interactions along the [100]
direction (Fig. 2), with intersheet spaces measuring 3.22(4) Å
and 3.30(1) Å in 2 and 1, respectively (see Fig. S1, ESI† for the
complete geometry of the stacking interaction). Furthermore,
chloride channels are assembled parallel to the stacking
direction. There are no non-classical hydrogen bonds involv-
ing the 3′-CH2 moiety of zalcitabine in its hydrochloride salt,
and the sulfur atom does not participate in significant inter-
molecular contacts in 1. The shortest separation between the
3′-CH2 carbon and a hydrogen bonding acceptor atom is
4.110(3) Å [C3′⋯O5′i (i) = −1 + x; y; z], ruling out the possibility
of the occurrence of any weak hydrogen bonding between them.
This reinforces the fact that the moiety at the 3′-position of the
5-membered ring does not drive the crystal structure of the cyti-
dine analogs. The geometrical parameters of the intermolecular
interactions present in 2 are listed in Table S3 in the ESI.†
Based on the isostructurality and chirality in the zalcita-
bine hydrochloride and lamivudine hydrochloride, we
decided to explore the crystallization of a two-drug system
in the form of a hydrochloride salt since it could lead to
either a physical mixture or a quasi-racemate. Quasi refers to
the 3′-position moiety differing for lamivudine and zalcita-
bine. After a few attempts, it was possible to crystallize this
multicomponent system from the same solvent matrix used
in the crystallization of the zalcitabine and lamivudine hydro-
chloride, using a 1 : 1 lamivudine : zalcitabine stoichiometry.
The two-drug salt 3 crystalizes in the triclinic space group P1
(Table S1, ESI†), showing a pseudo inversion center. One pro-
tonated molecule of lamivudine, one of zalcitabine, and two
chloride counterions compose the asymmetric unit (Fig. 3).
The same hydrogen bonding pattern between cytosine and a
chloride counterion in the chains found in the two isostructural
salts of only one API also occurs in the salt of both APIs (Fig. 4).
However, these chains are made up of either lamivudine or zal-
citabine in 3 rather than them alternating in every chain. These
chains therefore contain just one API. In addition, in 3 the NH2
hydrogen atom not involved in the pairing is hydrogen bonded
to a chloride counterion related by translation symmetry instead
of the screw axis present in 1 and 2 (see Fig. 2 and 4 for compari-
son). In 3, such chloride anion hydrogen bonding to the NH2
hydrogen not involved in the pairing is more coplanar to cytosine
than in 1 and 2. Furthermore, in 3 the paired chloride counter-
ion which accepts two hydrogen bonds from the cytosine of zal-
citabine is less coplanar with the heterocycle than the one not
involved in the pairing, which accepts only one hydrogen bond,
unlike what happens in 1, 2 and the chloride anion paired with
lamivudine in 3 (see Table S2, ESI† for planarity descriptors).
Even though lamivudine and zalcitabine are not alternate
in the chains running along the [100] direction, chains assem-
bled with either lamivudine or zalcitabine are running in the
opposite senses parallel to the [010] direction and are alter-
nately packed through offset face-to-face π–π stacking
Fig. 3 Asymmetric unit of the two-drug hydrochloride salt of zalcitabine and lamivudine (centre drawing with 50% probability ellipsoids and arbitrary
radius spheres for non-hydrogen and hydrogen atoms, respectively) and the conformations adopted by the APIs (side ball-and-stick depictions).
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interactions along the [010] direction, with stacking distances
of 3.28(2) Å and 3.35(6) Å (Fig. 4 and Fig. S1, ESI† for the com-
plete geometry of the stacking interaction). The largest stack-
ing distance occurs between neighboring chains which are
further stabilized through strong hydrogen bonds between
the hydroxyl group of either lamivudine (that with s.o. factors
of 40%) or zalcitabine and the chloride counterion paired
with one or the other stacked drug. This gives rise to a side
closed framework of two pseudo centrosymmetric chains,
namely, [(lamivudine)+Cl−]n and [(zalcitabine)
+Cl−]n (Fig. 4).
The geometry of all the hydrogen bonds present in 3 is shown
in Table S3 in the ESI.†
Is important to note that the hydrogen bond donation
from the hydroxyl group of molecules belonging to a given
chain to a chloride counterion of another one on top, as
observed in 3, is only possible due to the opposite chirality of
the asymmetry centers of the lamivudine and zalcitabine
molecules. This allows them to orientate both five-membered
rings towards the same interchain space and, consequently,
to form the O5′–H⋯Cl hydrogen bonds on both sides of the
face-to-face stacked chains. On the other hand, face-to-tail
stacking is required when only one API is present, as hap-
pens in 1 and 2. With this stacking mode, such a hydrogen
bond is sterically hindered to assemble on the two sides of
Fig. 4 Supramolecular structure of the zalcitabine–lamivudine hydrochloride salt 3. (a) One-dimensional chains made up of either only zalcitabine
or lamivudine grow along the a axis which are side-to-side packed parallel to the c axis, while they are alternately stacked along the b axis. (b) View
of the alternate face-to-face stacking along the b axis of a chain assembly with the cytosine stacking distances depicted. (c) Hydrogen bond pat-
tern responsible for assembling the drug chains (top and bottom illustrations) and for side closing two π-stacked chains related by pseudo
centrosymmetry (centre drawing). The antiparallel (API)+ → Cl− directions along the a axis are depicted (the 5′-CH2OH atomic fractions of
lamivudine with 60% occupancy are not exhibited). (d) API molecules are in contact along the [11−1] direction by means of π–π base stacking inter-
actions and hydrogen bonds between their 5′-OH moieties (that of lamivudine with an s.o. factor of 60% which is shown in this panel). Equivalent
positions: i = 1 + x; y; z; ii = −1 + x; y; z; iii = 1 + x; 1 + y; −1 + z.
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stacked chains. This stacking mode was observed in these
structures, although no hydrogen bond between the hydroxyl
moiety and chloride counterion takes place.
In addition, the other hydroxyl group fraction of lamivudine
with s.o. factors of 60% is a hydrogen bonding donor to the
hydroxyl oxygen of zalcitabine. This O5′L–H⋯O5′Z hydrogen
bond together with the π–π interaction having the largest sepa-
ration between stacked nucleobases are responsible for the
alternating lamivudine and zalcitabine along the [11−1] direc-
tion (Fig. 4).
As expected from our crystal engineering strategy based
on the isostructurality of 1 and 2, the cytosine and oxathio-
lane conformations in 3 show an anti and a C3′-endo pucker-
ing conformation, respectively (see Fig. 3 and Table S2, ESI†).
In this structure, the hydroxyl group of lamivudine with
major s.o. factors of 60% is in the equatorial position on the
same side as the sulfur, as in 1 (Table S2, ESI†). On the other
hand, in 3 the hydroxyl group of zalcitabine and that of
lamivudine with minor s.o. factors of 40% differ from those
observed in 1 and 2. They are in the equatorial position on
the opposite side of the 3′-position moiety (Table S2, ESI†).
The ability of cytidine-based nucleosides to form quasi-
enantiomeric crystals despite molecular differences in the
five-membered ring has also been assessed in ruthenium
coordination complexes containing lamivudine and cytidine.
We prepared transition metal coordination complexes of
cytidine-based nucleosides, namely, trans-[Ru(PPh3)2(3TC)
(bipy)]ClO4 (4) and trans-[Ru(PPh3)2(CYD)(bipy)]ClO4 (5),
where PPh3 means tryphenylphosphine, bipy refers to 2,2′-
bipyridine, and the ligands 3TC and CYD are lamivudinate
and cytidinate, respectively (Fig. 5).
Their asymmetric unit shows one cationic Ru(II) coordina-
tion complex in 4 and two in 5. The asymmetric unit of 4
contains one water and one acetone molecule as well as one
perchlorate counterion. The asymmetric unit of 5 contains
three water molecules and one methyl alcohol, all of them
with 50% s.o. factors each, one diethyl ether and two perchlo-
rate counterions (Fig. S2 and S3, ESI†). The structure of 4 was
solved in the orthorhombic space group P212121, while 5 crys-
tallized in the monoclinic space group P21 (Table S1, ESI†).
On analyzing the molecular geometry of the two com-
plexes, a distorted octahedral geometry around the ruthe-
nium(II) metal center is observed. The most important bond
lengths and angles around the coordination center of both
complexes are shown in Table S4 in the ESI.† All N–Ru–N
bond angles on the equatorial position are far from the
expected value of 90° in both complexes due to the tension of
the four and five-membered chelate rings. On the other hand,
in both cases, the P–Ru–N bond angles with less tension are
closer to 90°. Both complexes present the same stereo-
chemistry (Fig. 5), in which the phosphorus atoms of the
PPh3 ligand adopt a trans configuration with P1–Ru–P2 bond
angles close to 180°. Ellipsoid plots for 4 and 5 can be found
in the ESI† (Fig. S2 and S3).
Interestingly, the coordination geometry was identical in 4
and 5, in which both the lamivudine and cytidine ligands are
coordinated to Ru(II) as a anionic bidentate N,N-donor
through their imine N3 and deprotonated amine N4 nitrogen
atoms. In both cases, the N3 and N4 are trans to the nitrogen
atoms of the bipy ligand (N2 and N5). As can be seen in
Table S4 in the ESI,† the N3–C4 and C4–N4 bond lengths are
similar, suggesting that the N3–C4–N4 group forms a nega-
tively charged resonant moiety.
Cytosine adopts an intermediate conformation between
anti and syn in 4 and 5, while the five-membered ring
puckers with C1′ exo in 4 and also in one of the two crystallo-
graphically independent complex units of 5, namely, that
labeled as cytidine A (see the torsion angles in Table S5 in
the ESI†). Both the cytosine and sugar conformations are
unusual in canonical nucleosides, although they have been
previously reported in the lamivudine hydrochloride
hemihydrate.9a The conformation of the 5′-CH2OH branch in
Fig. 5 Ruthenium complexes with lamivudine and cytidine (top) can be related by a pseudo mirror plane (black line), as well as their nucleoside
ligands (shown on the bottom as they are in structures 4 and 5). Crystallographically independent cytidine ligand B conformationally differs mainly
for cytidine A and lamivudine due to C3′-endo puckering as a consequence of a hydrogen bond (dotted white line) between its hydroxyl moiety at
this position and the perchlorate counterion (shown).
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4 is also similar to that found in the cytidine A unit of 5. In
both cases, the OH oxygen atom at the C5′ axial position
points towards the same side of the 3′-position group (Fig. 5).
Both complexes also show a hydrogen bond between O5′ and
a water molecule.
Besides having the same coordination geometry, the
supramolecular building units are also conserved in 4 and 5
despite the differences in their molecular backbones, namely,
the presence of 2′-CH2 and 3′-S moieties in lamivudine rather
than CH2OH ones in cytidine. The structure of 4 is mainly
stabilized by hydrogen bonds in which the water molecule is
a double donor to both the hydroxyl and carbonyl oxygens of
the lamivudine ligand. This gives rise to an infinite 1D chain
along the [100] direction made up of alternate complexes and
water units (Fig. 6). In the chain backbone, there are only
translation-symmetry related complexes and water species.
In this structure, lamivudine is linked by a hydrogen bond to
the perchlorate counterion through its deprotonated amine
NH moiety (Fig. 6). The supramolecular interactions of 5
are similar to the ones found in 4 (Fig. 6). However, in 5,
each 4-like chain is assembled with either only cytidine A,
whose conformation is related to the lamivudine in 4 (Fig. 5),
or cytidine B. Indeed, cytidine B and the lamivudine-like cyti-
dine A differ because the cytosine and sugar moieties of cyti-
dine B are present in the anti and C3′-endo conformations
rather than in an intermediate conformation between syn
and anti and with C1′-exo, like in cytidine A and lamivudine.
The similarity between the cytidine ligands is in the 5′-OH
axial position. This conformational similarity reflects the
assembly of the one-dimensional chains, which occurs in 4
(Fig. 6).
In 5, the cytidine A units related by translation symmetry
are intercalated by one water molecule disordered over two
sites showing 50% occupancy each. One water fraction is
hydrogen bonded to one hydroxyl oxygen and the other one
to the carbonyl oxygen. Meanwhile, the units of cytidine B are
intercalated by a water molecule with just 50% of the occu-
pancy factor acting as a dual donor to the neighboring nucleo-
side molecules (Fig. 6). Perchlorate is also a hydrogen bond
acceptor from the deprotonated amine groups of both the
cytidine A and B units, like in 4. However, the perchlorate
counterion linked to the cytidine B unit accepts a hydrogen
bond from the hydroxyl moiety at the 3′-position of another
cytidine B unit related by a 21-screw axis. This last contact
helps to rationalize the C3′-endo puckering of cytidine B, con-
trasting to C1′-exo of cytidine A and lamivudine (Fig. 5).
4. Conclusions
The isostructurality between the single-drug hydrochloride
salts of lamivudine and zalcitabine reveals their ability to
assemble quasi-enantiomeric crystals even in multicomponent
crystal forms. The 3′-position moiety does not influence the
molecular conformation and supramolecular architecture of
the single-drug hydrochloride salts of lamivudine and zalcita-
bine, as also occurs in their anhydrate phases. Furthermore,
these quasi-enantiomeric hydrochloride salts are able to form a
quasi-racemate when crystallized together. The two-drug hydro-
chloride salt of lamivudine and zalcitabine has pseudo centrosym-
metric chains assembled with either lamivudine or zalcitabine
and chloride units. Based on this finding, we believe that the
tendency of quasi-enantiomeric nucleosides to assemble quasi-
racemates should be better explored when searching for new
multicomponent crystal forms thereof.
The first examples of transition metal coordination complexes
containing cytidine analogs, trans-bis-(triphenylphosphine)
(lamivudinate)(2,2′-bipyridine)ruthenium(II) perchlorate and
trans-bis-(triphenylphosphine)(cytidinate)(2,2′-bipyridine)
ruthenium(II) perchlorate complexes were reported in this
study. They show the same coordination geometry and similar
supramolecular building blocks despite the presence of 2′-CH2
and 3′-S moieties in lamivudine rather than CH2OH ones in
Fig. 6 Packing of the ruthenium complexes with nucleoside ligands
showing the pseudo mirror plane (black line). The PPh3 moieties were
omitted for clarity. Chains containing the cytidine A units are assembled
though hydrogen bonds to water molecules disordered over two
position showing a 50% occupancy factor each, while those containing
cytidine B units show just one-site 50% occupancy water molecules. The
geometries of the main hydrogen bonds stabilizing the crystal structures
of 4 and 5 are shown in Table S6 in the ESI.†
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cytidine. Therefore, the effect of these 2′,3′-positions groups in
the crystal structure seems to be negligible as well as in the
hydrochloride salts.
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